^Quang LS, Desai MC, Kraner JC, Shannon MW, Woolf AD, Maher TJ (June 2002). "Enzyme and receptor antagonists for preventing toxicity from the gamma-hydroxybutyric acid precursor 1,4-butanediol in CD-1 mice". Annals of the New York Academy of Sciences. 965 (1): 461–472.
Bibcode:
2002NYASA.965..461Q.
doi:
10.1111/j.1749-6632.2002.tb04187.x.
PMID12105121.
S2CID25644267.
^
abcBourguignon JJ, Schoenfelder A, Schmitt M, Wermuth CG, Hechler V, Charlier B, Maitre M (May 1988). "Analogues of gamma-hydroxybutyric acid. Synthesis and binding studies". Journal of Medicinal Chemistry. 31 (5): 893–897.
doi:
10.1021/jm00400a001.
PMID3361576.
^Vayer P, Dessort D, Bourguignon JJ, Wermuth CG, Mandel P, Maitre M (July 1985). "Natural occurrence of trans-gamma hydroxycrotonic acid in rat brain". Biochemical Pharmacology. 34 (13): 2401–2404.
doi:
10.1016/0006-2952(85)90804-4.
PMID4015683.
^Wellendorph P, Høg S, Greenwood JR, de Lichtenberg A, Nielsen B, Frølund B, et al. (October 2005). "Novel cyclic gamma-hydroxybutyrate (GHB) analogs with high affinity and stereoselectivity of binding to GHB sites in rat brain". The Journal of Pharmacology and Experimental Therapeutics. 315 (1): 346–351.
doi:
10.1124/jpet.105.090472.
PMID16014570.
S2CID10332754.
^
abCastelli MP, Ferraro L, Mocci I, Carta F, Carai MA, Antonelli T, et al. (November 2003). "Selective gamma-hydroxybutyric acid receptor ligands increase extracellular glutamate in the hippocampus, but fail to activate G protein and to produce the sedative/hypnotic effect of gamma-hydroxybutyric acid". Journal of Neurochemistry. 87 (3): 722–732.
doi:
10.1046/j.1471-4159.2003.02037.x.
PMID14535954.
S2CID82175813.